US Patent No: 7,749,542

Number of patents in Portfolio can not be more than 2000

Opioid agonist/antagonist combinations

ALSO PUBLISHED AS: 20080292694
3 Status Updates

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention is directed in part to oral dosage forms comprising a combination of an orally analgesically effective amount of an opioid agonist and an orally active opioid antagonist, the opioid antagonist being included in a ratio to the opioid agonist to provide a combination product which is analgesically effective when the combination is administered orally, but which is aversive in a physically dependent subject. Preferably, the amount of opioid antagonist included in the combination product provides at least a mildly negative, “aversive” experience in physically dependent addicts (e.g., precipitated abstinence syndrome).

Loading the Abstract Image... loading....

First Claim

See full text

all claims..

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddressTotal Patents
PURDUE PHARMA L.P.STAMFORD, CT273

International Classification(s)

  • [Classification Symbol]
  • [Patents Count]

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Colucci, Robert D Newtown, CT 28 820
Kaiko, Robert F Weston, CT 51 1333

Cited Art Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (39)
4,828,836 Controlled release pharmaceutical composition 171 1987
4,834,985 Controlled release pharmaceutical composition 189 1987
4,990,341 Controlled release hydromorphone composition 113 1989
5,266,331 Controlled release oxycodone compositions 139 1991
5,273,760 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 177 1991
5,286,493 Stabilized controlled release formulations having acrylic polymer coating 173 1992
5,549,912 Controlled release oxycodone compositions 131 1993
5,472,712 Controlled-release formulations coated with aqueous dispersions of ethylcellulose 158 1993
5,478,577 Method of treating pain by administering 24 hour oral opioid formulations exhibiting rapid rate of initial rise of plasma drug level 148 1993
5,411,745 Powder-layered morphine sulfate formulations 91 1994
5,965,161 Extruded multi-particulates 106 1994
5,639,476 Controlled release formulations coated with aqueous dispersions of acrylic polymers 349 1995
5,508,042 Controlled release oxycodone compositions 140 1995
5,968,551 Orally administrable opioid formulations having extended duration of effect 149 1995
5,958,459 Opioid formulations having extended controlled released 87 1995
5,656,295 Controlled release oxycodone compositions 118 1996
5,681,585 Stabilized controlled release substrate having a coating derived from an aqueous dispersion of hydrophobic polymer 85 1996
5,672,360 Method of treating pain by administering 24 hour oral opioid formulations 146 1996
6,143,322 Method of treating humans with opioid formulations having extended controlled release 98 1997
5,958,452 Extruded orally administrable opioid formulations 135 1997
5,968,547 Method of providing sustained analgesia with buprenorphine 80 1997
6,077,533 Powder-layered oral dosage forms 58 1998
6,228,863 Method of preventing abuse of opioid dosage forms 131 1998
* 6,277,384 Opioid agonist/antagonist combinations 94 1998
6,103,261 Opioid formulations having extended controlled release 98 1999
6,335,033 Melt-extrusion multiparticulates 69 1999
6,261,599 Melt-extruded orally administrable opioid formulations 112 1999
6,294,195 Orally administrable opioid formulations having extended duration of effect 96 1999
6,375,957 Opioid agonist/opioid antagonist/acetaminophen combinations 120 2000
6,696,088 Tamper-resistant oral opioid agonist formulations 98 2001
* 6,475,494 Opioid agonist/antagonist combinations 70 2001
2003/0069,263 Pharmaceutical combinations of oxycodone and naloxone 48 2002
2003/0073,714 Opioid agonist formulations with releasable and sequestered antagonist 47 2002
* 6,696,066 Opioid agonist/antagonist combinations 92 2002
2003/0229,111 Naltrexone hydrochloride compositions 16 2003
2004/0186,121 Tamper-resistant oral opioid agonist formulations 40 2003
* 7,172,767 Opioid agonist / antagonist combinations 53 2003
2006/0182,801 Sequestered antagonist formulations 36 2006
* 7,419,686 Opioid agonist/antagonist combinations 28 2006
 
EURO-CELTIQUE S.A. (35)
4,366,310 Controlled release compositions 48 1980
4,940,587 Oral pharmaceutical composition through mucosa 104 1986
4,844,907 Pharmaceutical composition comprising analgesic and anti-inflammatory agent 121 1986
4,834,965 Controlled release pharmaceutical composition 80 1987
4,867,985 Spheroids 83 1988
5,071,646 Pharmaceutical ion exchange resin composition 105 1989
5,091,189 Controlled release dosage forms having a defined water content 42 1991
5,215,758 Controlled release matrix suppository for pharmaceuticals 78 1991
5,324,351 Aqueous dispersions of zein and preparation thereof 90 1992
5,356,467 Controlled release coatings derived from aqueous dispersions of zein 135 1993
5,500,227 Immediate release tablet cores of insoluble drugs having sustained-release coating 131 1993
5,622,722 Spheroid formulation 41 1994
5,508,043 Controlled release matrix for pharmaceuticals 49 1995
5,670,172 Pharmaceutical spheroid formulation 65 1995
6,024,982 Immediate release tablet cores of insoluble drugs having sustained-release coating 88 1995
5,811,126 Controlled release matrix for pharmaceuticals 71 1995
5,763,452 Pharmaceutical compositions and usages 40 1996
5,849,240 Method of preparing sustained release pharmaceutical compositions 100 1996
5,891,471 Pharmaceutical multiparticulates 88 1996
5,601,845 Pharmaceutical spheroid formulation 84 1996
5,843,480 Controlled release diamorphine formulation 68 1996
5,879,705 Sustained release compositions of morphine and a method of preparing pharmaceutical compositions 91 1997
5,908,848 Synergistic composition of codine and ibuprofen to treat arthritis 42 1997
5,942,241 Formulations and methods for providing prolonged local anesthesia 114 1997
6,068,855 Pharmaceutical composition containing a fusible carrier and method for producing the same 63 1997
5,965,163 Substained release compositions and a method of preparing pharmaceutical compositions 97 1997
6,077,532 Pharmaceutical ion exchange resin composition 48 1998
6,306,438 Stabilized sustained release tramadol formulations 64 1998
6,399,096 Pharmaceutical formulation 61 1998
6,143,328 Sustained release compositions and a method of preparing pharmaceutical compositions 50 1999
6,162,467 Sustained release compositions and a method of preparing pharmaceutical compositions 71 1999
6,210,714 Immediate release tablet cores of acetaminophen having sustained-release coating 69 2000
6,387,404 Immediate release tablet cores of insoluble drugs having sustained-release coating 70 2001
6,716,449 Controlled-release compositions containing opioid agonist and antagonist 69 2001
6,627,635 Method of preventing abuse of opioid dosage forms 81 2001
 
ALBERT EINSTEIN COLLEGE OF MEDICINE OF YESHIVA UNIVERSITY (12)
5,472,943 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists 87 1993
5,585,348 Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia 74 1993
* 5,512,578 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists 95 1994
5,624,932 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 48 1995
* 5,580,876 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 77 1995
5,767,125 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 80 1996
6,096,756 Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 77 1998
6,194,382 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 48 1999
2001/0006,967 METHOD OF SIMULTANEOUSLY ENHANCING ANALGESIC POTENCY AND ATTENUATING ADVERSE SIDE EFFECTS CAUSED BY TRAMADOL AND OTHER BIMODALLY-ACTING OPIOID AGONISTS 19 1999
6,362,194 Method and simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists 38 2000
6,395,705 Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists 45 2001
6,765,010 Compositions and methods for enhancing analgesic potency of tramadol and attenuating its adverse side effects 39 2002
 
MERCK FROSST CANADA LTD. (10)
5,409,944 Alkanesulfonamido-1-indanone derivatives as inhibitors of cyclooxygenase 71 1993
5,604,260 5-methanesulfonamido-1-indanones as an inhibitor of cyclooxygenase-2 83 1993
5,436,265 1-aroyl-3-indolyl alkanoic acids and derivatives thereof useful as anti-inflammatory agents 87 1993
5,521,213 Diaryl bicyclic heterocycles as inhibitors of cyclooxygenase-2 93 1994
5,552,422 Aryl substituted 5,5 fused aromatic nitrogen compounds as anti-inflammatory agents 101 1995
5,536,752 Phenyl heterocycles as COX-2 inhibitors 79 1995
5,550,142 Phenyl heterocycles as cox-2 inhibitors 85 1995
5,510,368 N-benzyl-3-indoleacetic acids as antiinflammatory drugs 89 1995
5,604,253 N-benzylindol-3-yl propanoic acid derivatives as cyclooxygenase inhibitors 72 1995
5,639,780 N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors 71 1995
 
REGENTS OF THE UNIVERSITY OF MINNESOTA (6)
4,401,672 Non-addictive narcotic antitussive preparation 61 1981
4,730,048 Gut-selective opiates 82 1985
5,352,680 Delta opioid receptor antagonists to block opioid agonist tolerance and dependence 101 1992
5,457,208 Kappa opioid receptor antagonists 73 1993
5,578,725 Delta opioid receptor antagonists 55 1995
5,780,479 Use of opioid antagonists to treat impulse-control disorders 51 1997
 
ALZA CORPORATION (4)
4,573,995 Transdermal therapeutic systems for the administration of naloxone, naltrexone and nalbuphine 136 1984
5,236,714 Abusable substance dosage form having reduced abuse potential 97 1988
5,460,826 Morphine therapy 90 1994
5,866,164 Composition and dosage form comprising opioid antagonist 121 1997
 
UNIVERSITY OF CHICAGO, THE (4)
4,719,215 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 86 1986
4,861,781 Quaternary derivatives of noroxymorphone which relieve nausea and emesis 81 1987
5,102,887 Method for reducing emesis and nausea induced by the administration of an emesis causing agent 81 1990
5,972,954 Use of methylnaltrexone and related compounds 95 1997
 
VIRGINIA COMMONWEALTH UNIVERSITY (4)
5,352,683 Method for the treatment of chronic pain 81 1993
5,321,012 Inhibiting the development of tolerance to and/or dependence on a narcotic addictive substance 121 1993
5,502,058 Method for the treatment of pain 102 1994
5,556,838 Inhibiting the development of tolerance to and/or dependence on an addictive substance 114 1994
 
CONTRAL CLINICS OY (3)
4,882,335 Method for treating alcohol-drinking response 75 1988
5,096,715 Method and means for treating alcoholism by extinguishing the alcohol-drinking response using a transdermally administered opiate antagonist 58 1989
5,086,058 Method for treating alcoholism with nalmefene 73 1990
 
NAPP PHARMACEUTICAL GROUP LIMITED (3)
5,591,452 Controlled release formulation 85 1994
6,326,027 Controlled release formulation 76 1995
6,254,887 Controlled release tramadol 72 1996
 
The Rockefeller University (3)
4,987,136 Method for controlling gastrointestinal dysmotility 111 1986
4,769,372 Method of treating patients suffering from chronic pain or chronic cough 85 1986
4,785,000 Method of treating patients suffering from chronic pain or chronic cough 63 1987
 
BASF AKTIENGESELLSCHAFT (2)
4,806,558 Diarylacetylenes and their use in treating acne 53 1985
4,957,681 Preparation of pharmaceutical mixtures 91 1989
 
E. I. DU PONT DE NEMOURS AND COMPANY (2)
4,451,470 Analgesic, antagonist, and/or anorectic 14-fluoromorphinans 62 1982
5,593,994 Prostaglandin synthase inhibitors 66 1994
 
EUROCELTIQUE S.A., 122, BOULEVARD DE LA PETRUSSE, LUXEMBOURG (2)
4,844,909 Controlled release hydromorphone composition 107 1987
4,844,910 Spheroids 51 1987
 
NOVA PHARMACEUTICAL CORPORATION (2)
4,760,069 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 66 1985
4,889,860 Oximes of oxymorphone, naltrexone and naloxone as potent, selective opioid receptor agonists and antagonists 69 1987
 
OMEROS CORPORATION (2)
5,858,017 Urologic irrigation solution and method for inhibition of pain, inflammation and spasm 105 1996
5,860,950 Arthroscopic irrigation solution and method for inhibition of pain and inflammation 91 1996
 
PURDUE PHARMA COMPANY, THE (2)
4,861,598 Controlled release bases for pharmaceuticals 140 1986
4,970,075 Controlled release bases for pharmaceuticals 114 1989
 
RECKITT BENCKISER HEALTHCARE (UK) LIMITED (2)
4,582,835 Analgesic compositions 107 1984
4,661,492 Analgesic compositions 73 1985
 
Schaap; Robert J. (2)
5,316,759 Agonist-antagonist combination to reduce the use of nicotine and other drugs 68 1992
5,574,052 Agonist-antagonist combination to reduce the use of nicotine and other drugs 119 1994
 
ADIR ET COMPAGNIE (1)
5,130,311 Oxazolopyridine compounds, compositions and use 49 1991
 
Aminotek Sciences, Inc. (1)
5,256,669 Methods and compositions for treating acute or chronic pain and drug addiction 59 1992
 
BAKER NORTON PHARMACEUTICALS, INC. (1)
4,873,076 Method of safely providing anesthesia or conscious sedation 62 1989
 
BRISTOL-MYERS SQUIBB COMPANY (1)
4,457,933 Prevention of analgesic abuse 103 1981
 
COLMAN PRODUCTS LIMITED (1)
4,935,428 Treating opiate dependence 72 1988
 
DUPONT MERCK PHARMACEUTICAL COMPANY, THE (1)
4,722,928 N-oxide prodrug derivatives of 3-hydroxy morphinans and partial morphinans having improved oral bioavailability, pharmaceutical compositions, and processes 24 1985
 
DYNAGEN, INC. (1)
5,486,362 Controlled, sustained release delivery system for treating drug dependency 98 1993
 
Eli Lilly and Company (1)
5,998,434 Composition for treating pain 46 1998
 
ENCINAL PHARMACEUTICAL INVESTMENTS, LLC (1)
5,869,097 Method of therapy comprising an osmotic caplet 61 1992
 
G. D. Searle & Co. (1)
5,616,601 1,2-aryl and heteroaryl substituted imidazolyl compounds for the treatment of inflammation 118 1995
 
GENERAL ELECTRIC COMPANY (1)
5,226,331 Apparatus and method for measuring the particle number rate and the velocity distribution of a sprayed stream 43 1991
 
ICN HUNGARY RT. (1)
5,317,022 Pharmaceutical composition and use 58 1992
 
LIFESHIELD SCIENCES LLC (1)
2004/0158,312 Braided endoluminal device having tapered filaments 6 2003
 
McGinnis; Carolyn (1)
4,608,376 Opiate agonists and antagonists 51 1982
 
MERCK FROSST COMPANY (1)
5,474,995 Phenyl heterocycles as cox-2 inhibitors 151 1994
 
MERCK SHARP & DOHME LTD. (1)
5,880,132 Tachykinin antagonist and an opioid analgesic effective at treating pain or nociception 58 1997
 
NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT (1)
5,225,440 Attenuation of the opioid withdrawal syndrome by inhibitors of nitric oxide synthase 58 1991
 
OREGON, UNIVERSITY OF (1)
5,514,680 Glycine receptor antagonists and the use thereof 67 1993
 
ORTHO-MCNEIL PHARMACEUTICAL, INC. (1)
5,336,691 Composition comprising a tramadol material and acetaminophen and its use 75 1992
 
PEPTECH LIMITED (1)
5,534,492 Muramyl peptide for the treatment of toxicity 48 1995
 
PUREUE PHARMA L.P. (1)
4,834,984 Controlled release dihydrocodeine composition 101 1987
 
RUTGERS, STATE UNIVERSITY OF NEW JERSEY, THE, OLD QUEEN BUILDING, SOMERSET AND GEORGE STREETS, NEW BRUNSWICK, NJ 08903 (1)
4,806,341 Transdermal absorption dosage unit for narcotic analgesics and antagonists and process for administration 114 1986
 
SCULLY SCOTT MURPHY & PRESSER, PC (1)
5,426,112 Growth regulation and related applications of opioid antagonists 89 1993
 
SIMON, DAVID L. (1)
6,103,258 Salts and bases of the 17-(Cyclopropylmethyl)-4,5 alpha-epoxy-6-Methylenemorphinan-3,14 diol molecule for optimizing dopamine homeostasis during administration of opioid analgesics 45 1998
 
SLOAN-KETTERING INSTITUTE FOR CANCER RESEARCH (1)
4,803,208 Opiate agonists and antagonists 55 1985
 
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (1)
4,806,543 Method and compositions for reducing neurotoxic injury 77 1986
 
The Lynx Project Limited (1)
6,310,072 Production of analgesic synergy by co-administration of sub-analgesic doses of a MU opioid agonist and a kappa-2 opioid agonist 47 1997
 
THE MCLEAN HOSPITAL CORPORATION (1)
5,075,341 Treatment for cocaine abuse 120 1989
 
The United States of America as represented by the Secretary of the Army (1)
5,834,477 Opiate analgesic formulation with improved safety 41 1994
 
United Biomedical, Inc. (1)
5,633,259 Method for identification of low/non-addictive opioid analgesics and the use of said analgesics for treatment of opioid addiction 50 1995
 
Warner-Lambert Company (1)
5,149,538 Misuse-resistive transdermal opioid dosage form 142 1991
 
YOUNG, JACQUELINE, MS. (1)
5,356,900 Method of treating chronic herpes virus infections using an opiate receptor antagonist 55 1993
 
Other [Check patent profile for assignment information] (7)
4,464,378 Method of administering narcotic antagonists and analgesics and novel dosage forms containing same 147 1981
4,443,428 Extended action controlled release compositions 84 1982
5,376,662 Method of attenuating nerve injury induced pain 53 1993
2004/0092,542 Tamper-resistant oral opioid agonist formulations 34 2003
2005/0095,291 Tamper-resistant oral opioid agonist formulations 45 2003
2005/0181,046 Tamper-resistant oral opioid agonist formulations 31 2003
2006/0039,970 Tamper-resistant oral opioid agonist formulations 22 2003
* Cited By Examiner

Patent Citation Ranking

Forward Cite Landscape

Patent Info (Count) # Cites Year
 
PURDUE PHARMA L.P. (8)
8,518,925 Opioids for the treatment of the chronic obstructive pulmonary disease (COPD) 0 2005
* 8,105,631 Opioid agonist/antagonist combinations 10 2010
8,673,355 Opioid agonist/antagonist combinations 0 2011
8,846,090 Matrix for sustained, invariant and independent release of active compounds 0 2012
8,822,487 Opioid agonist/opioid antagonist/acetaminophen combinations 0 2012
8,846,091 Matrix for sustained, invariant and independent release of active compounds 0 2013
8,936,808 Opioid agonist/opioid antagonist/acetaminophen combinations 0 2014
8,932,630 Opioid agonist/antagonist combinations 0 2014
 
EGALET LTD. (2)
8,877,241 Morphine controlled release system 0 2004
8,808,745 Morphine polymer release system 0 2013
 
QRXPHARMA LTD. (1)
* 8,933,092 Methods and compositions comprising sequential administration opioid receptor agonists 0 2012
* Cited By Examiner

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
7.5 Year Payment $3600.00 $1800.00 $900.00 Jan 6, 2018
11.5 Year Payment $7400.00 $3700.00 $1850.00 Jan 6, 2022
Fee Large entity fee small entity fee micro entity fee
Surcharge - 7.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00